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ABSTRACT
Several large phase III trials have demonstrated that
tamoxifen—and more recently, raloxifene—can effec-
tively reduce the incidence of invasive breast cancer
by 50%. However, these selective estrogen receptor
modulators can also be associated with several rare,
but serious, adverse events. Recently, the third-gen-
eration aromatase inhibitors (AIs) have demonstrated
excellent efficacy in adjuvant breast cancer trials, and
they show particular promise in the breast cancer pre-
vention setting. The National Cancer Institute of
Canada Clinical Trials Group (NCIC CTG) has devel-
oped a randomized phase III study to determine the
efficacy of an AI (exemestane) to reduce the incidence
of invasive breast cancer in postmenopausal women
at an increased risk for developing breast cancer. The
NCIC CTG MAP.3 (ExCel) trial is a double-blind placebo-
controlled multicentre, multinational trial. Based on
the known preclinical and clinical profile of the AIs, a
greater reduction in breast cancer incidence with fewer
side effects is hypothesized with this class of agents
than with tamoxifen or raloxifene.
KEY WORDS
Aromatase inhibitors, breast cancer risk reduction,
chemoprevention
1. INTRODUCTION
Breast cancer is one of the most frequently diagnosed
malignancies in women worldwide. In North
America, it represents about 30% of all cancers and
about 20% of all cancer-related deaths. In the United
States and Canada respectively, more than 200,000
and 20,000 new breast cancer cases are diagnosed
annually, and beginning in the 1980s and continuing
until very recently, the incidence of breast cancer was
rising at a rate of approximately 2% per year 1,2.
The epidemiology of breast cancer is strongly
influenced by genetic and environmental factors.
Compared with other women, women with breast
cancer are about twice as likely to have a first-degree
relative with breast cancer, suggesting that the ge-
netic factors are important determinants of disease
risk 3–5. However, large international differences in
the rates of breast cancer and changes in the rates of
disease in migrants from low-risk to high-risk coun-
tries suggest that environmental factors also play an
important causative role 6–8.
Decades of epidemiologic and laboratory research
have also identified that hormonal exposures are im-
portant in the complex origins of breast cancer. Hor-
monal events such as early age at menarche, late age
at parity, and late onset of menopause can all increase
breast cancer risk 9.10. To date, most research has fo-
cused on endogenous sex steroid exposure, and higher
levels of estrogen and androgens have been shown to
be associated with a modest increase in the risk of
breast cancer in pre- and postmenopausal women 11–13.
Interest in studying the roles of other hormones such
as prolactin 14 and the insulin–insulin-like growth fac-
tor (IGF) axis 15 is increasing, based on recent preclini-
cal studies demonstrating the important role that IGF-1
plays in stimulating the growth of prostate and breast
cancer cells alike 16.
Many of the established risk factors currently
identified for breast cancer cannot be easily modi-
fied. However, improved diet and reduced body
weight, alcohol intake, hormone use, and mammo-
graphic density are examples of factors that can 17–21.
At the 29th annual San Antonio Breast Cancer Sym-
posium, Dr. Ravdin and colleagues from the National
Cancer Institute and Harbor University of Califor-
nia, Los Angeles Medical Center, reported on an over-
all 7% decline in breast cancer incidence from 2002
to 2003 2, based on data from the Surveillance Epi-
demiology and Endpoints Results database. He noted
that the decline was greatest in women over 50 years
of age. Similar data have also been observed in Cali-
fornia over the same time period and for 2004 22.
Dr. Ravdin and his team speculate that the dra-
matic reduction in use of hormone replacement
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therapy (HRT) in 2002 may be the best explanation
for the reduction in breast cancer occurrence. Fol-
lowing the disappointing findings in 2002 from the
Women’s Health Initiative Study of combination es-
trogen and progestin, which demonstrated a statisti-
cally significant increase (24%) in the breast cancer
risk in the treatment arm, HRT prescribing patterns
were significantly altered 20. Clarke and colleagues
showed that hormone therapy use dropped 68% be-
tween 2001 and 2003 in California, and shortly there-
after breast cancer rates dropped by 10%–11% 22.
That decline was sustained in 2004.
Breast cancer may take decades to grow, but many
of these cancers are believed to be fuelled by hor-
mones such as estrogen. By cutting the fuel supply,
tumour growth is slowed down substantially—and
possibly stopped. In turn, these tumours may be
harder to detect by mammography. If estrogen can
act as a promoter of tumour growth, it is possible
that a change in HRT use could translate into a full 7%
reduction in breast cancer occurrence 1 year later,
based on the high prevalence of HRT use in postmeno-
pausal women before 2002 2.
2. BREAST CANCER CHEMOPREVENTION
The foregoing data and other epidemiologic studies
have prompted researchers to hypothesize about strat-
egies that may reduce the frequency of breast cancer.
One logical strategy is to investigate agents capable of
interfering with the initiation or promotion of the dis-
ease—in other words, breast cancer chemoprevention.
To date, chemoprevention research has focused
on strategies directed at antagonizing the effects of
estrogens, because these hormones are known to play
a key role both in the development of the normal
breast and in the pathogenesis of breast cancer 23,24.
In principle, at least two pharmacologic approaches
may be used to antagonize the effects of estrogen in
the breast. The first is to inhibit estrogen binding to
its receptor by using selective estrogen receptor
modulators (SERMs—tamoxifen and raloxifene). An
alternative strategy of antagonizing (reducing) the
effects of estrogen is to inhibit estrogen synthesis with
an aromatase (estrogen synthetase) inhibitor (AI).
2.1 Inhibition of Estrogen Binding
Tamoxifen and raloxifene have both been shown to
reduce the incidence of invasive breast cancer by up
to 50% in pre- and postmenopausal women at high
risk 25–27. Both drugs only reduce the incidence of es-
trogen receptor–positive breast cancer, consistent with
their mode of action as SERMs. As a result, tamoxifen
was approved by the U.S. Food and Drug Adminis-
tration (FDA) for short-term reduction in the incidence
of ductal carcinoma in situ (DCIS) and invasive breast
cancer in women at increased risk. Raloxifene is cur-
rently under review by the FDA for approval as a sec-
ond chemopreventive agent for women at high risk of
developing invasive breast cancer. In fact, tamoxifen
and raloxifene both appear effective in reducing breast
cancer risk in “all risk” individuals as well, but ap-
proval for tamoxifen was granted by the FDA only for
use in high-risk women because of its complicated
therapeutic index. In particular, tamoxifen can cause
rare, but serious, adverse events, including endome-
trial cancer and thromboembolic disease, especially
in older postmenopausal women 28.
2.2 Inhibition of Estrogen Synthesis
The effect of AIs on risk of breast cancer in postmeno-
pausal women is currently under study. The National
Cancer Institute of Canada Clinical Trials Group (NCIC
CTG) MAP.3 trial is one such study designed to examine
the efficacy of exemestane versus placebo in postmeno-
pausal women at increased risk of developing breast
cancer. The International Breast Cancer Intervention
Study 2 (IBIS 2), initiated in 2004, is the only other
large, phase III trial designed to evaluate the efficacy
of anastrozole as compared with placebo in prevent-
ing invasive breast cancer. It is underway in a simi-
larly high-risk population in the United Kingdom 29.
3. AROMATASE INHIBITORS AS POTENTIAL
CHEMOPREVENTIVE AGENTS
Targeting and reducing estrogen synthesis is a way
of preventing estradiol from stimulating the estrogen
receptor and of reducing the formation of cancer-caus-
ing catechol metabolites of estrogen. To that end, AIs
were developed.
Aromatase is the enzyme complex responsible
for the final step in estrogen biosynthesis: the con-
version of androgens to estrogens. The third-genera-
tion  AIs letrozole, anastrozole, and exemestane are
all approved for use in postmenopausal women with
estrogen receptor–positive metastatic breast cancer
that has progressed after tamoxifen or failed to re-
spond to tamoxifen 30–33, or as initial therapy in treat-
ment-naïve women with receptor-positive metastatic
disease. In addition, the FDA and Health Canada have
approved anastrozole, exemestane, and letrozole for
use as adjuvant therapy for postmenopausal women
with hormone receptor–positive breast cancer follow-
ing varying periods of treatment with tamoxifen.
At least eight adjuvant trials are currently testing
AIs in early-stage postmenopausal receptor-positive
breast cancer. Published data from four large phase III
double-blind randomized adjuvant trials comparing
third-generation AIs with tamoxifen or placebo after
5 or fewer years of tamoxifen are currently available.
In the Arimidex, Tamoxifen Alone or in Combi-
nation (ATAC) trial, 9366 patients were randomly as-
signed to receive anastrozole and placebo, tamoxifen
and placebo, or anastrozole and tamoxifen combined.
Disease-free survival was significantly lengthenedRICHARDSON et al.
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when the anastrozole group was compared with the
tamoxifen group (absolute risk reduction: 2.7%;
p = 0.013) after a median follow-up of 47 months.
Importantly, the incidence of new contralateral pri-
mary breast cancer was significantly lower in the
anastrozole group than in the tamoxifen group [odds
ratio (OR): 0.42; p = 0.007] 34.
The Intergroup Exemestane Study (IES) randomly
assigned 4742 women who had received 2–3 years of
tamoxifen to continue tamoxifen for a total of 5 years
or to switch to exemestane to complete a 5-year course
of hormonal therapy. After a median follow-up of
56 months, a significant improvement in disease-free
survival was observed in the exemestane group [hazard
ratio (HR): 0.76; 95% confidence interval (CI): 0.66 to
0.88], together with a significant reduction in contralat-
eral breast cancer events (HR: 0.56; 95% CI: 0.32 to
0.97) 35 and a modest improvement in overall survival 36.
The NCIC CTG MA.17 trial involved 5187 postmeno-
pausal women who had taken tamoxifen for 5 years
and who were disease free at time of study entry. They
were randomly assigned to receive 5 years of letrozole
or 5 years of placebo. The study was halted by the
Data Safety Monitoring Committee after a median of
2.4 years because of a significant reduction in breast
cancer events in the treatment arm 37. More recently,
the study demonstrated an overall benefit in distant
disease-free survival and a survival advantage in the
subset of women on the trial who had node-positive
disease. The incidence of contralateral cancers was
also lower in the letrozole group, although the differ-
ence was not statistically significant 38.
The Breast Cancer International Study Group
involved approximately 8000 women and had four
treatment arms: tamoxifen alone for 5 years, letrozole
alone for 5 years, tamoxifen for 3 years followed by
letrozole for 2 years, and letrozole for 3 years fol-
lowed by tamoxifen for 2 years. A recent analysis
comparing letrozole to tamoxifen treatment showed
that the reduction in risk of recurrence or death was
19% lower in the letrozole-alone group after a me-
dian of 28 months of follow-up. Comparisons of the
switched arms are not yet available 39.
Based on results from these large trials and other
smaller randomized trials, the Technology Assess-
ment of Aromatase Inhibitors Status Report 2004
from the American Society of Clinical Oncology
(ASCO) recommends that, to lower the risk of recur-
rence, adjuvant therapy for postmenopausal women
with hormone receptor–positive breast cancer should
include  AIs. The optimal timing and duration of AI
therapy has yet to be established 40.
The thus-far convincing evidence that the AIs are
superior to tamoxifen in the treatment of breast can-
cer has suggested that they will also perhaps prove
to be superior in the chemopreventive setting.
Exemestane is a third-generation irreversible ste-
roidal aromatase inactivator, structurally related to
the natural substrate androstenedione. In postmeno-
pausal women, exemestane is capable of inhibiting
aromatase action by more than 95%. The reduction
in contralateral breast cancer incidence in the ATAC
and IES trials is especially promising in this regard.
In addition to the clinical studies, a significant
body of data on the chemopreventive properties of
AIs comes from preclinical studies 41–44.
4. NCIC CTG MAP.3
The MAP.3 (ExCel) trial (www.excelstudy.com) is a
randomized double-blind placebo-controlled, multi-
centre, multinational trial sponsored by the NCIC CTG
and supported by Pfizer Inc. Based on the known pre-
clinical and clinical profile of the AIs, a greater reduc-
tion in breast cancer incidence is hypothesized with
this class of agents than with tamoxifen or raloxifene.
4.1 Study Design
The initial intent was to compare exemestane (25 mg)
in combination with a cyclooxygenase enzyme 2
(COX-2) inhibitor, celecoxib (400 mg); exemestane
(25 mg) in combination with a placebo; and a placebo
(2 tablets) in a phase III randomized trial, in 5100 post-
menopausal women at increased risk of developing
breast cancer. The rationale for incorporating
celecoxib into the trial design was based on observa-
tions that COX-2 is overexpressed in breast cancer and
in pre-invasive breast lesions 45–47, and that a meta-
analysis of 14 cohort and case-control studies had
found a combined relative risk of 0.82 (95% CI: 0.75
to 0.89) for developing breast cancer in women who
had a history of taking COX-2 inhibitors 48. Further-
more, in preclinical studies, a synergistic effect ap-
peared to exist between celecoxib and exemestane,
resulting in a greater ability to prevent new tumours
and to reduce the existing tumour burden in animals
when the drugs were combined 49. At the time that the
MAP.3 protocol was developed, celecoxib was consid-
ered to be well tolerated and safe.
Each of the three arms was to be tested separately
and consecutively. Celecoxib–placebo was to be pre-
scribed for a total of 3 years, and exemestane–pla-
cebo was to be prescribed for a total of 5 years. The
original MAP.3 protocol was activated in 2004, and
the first 35 participants were enrolled between Sep-
tember and November 2004.
Unfortunately, in September 2004, early results
from a colorectal adenoma chemoprevention trial
(APPROVe) 50 showed an elevated cardiovascular risk
in subjects with a history of colorectal adenomas who
were taking rofecoxib (Vioxx: Merck, Whitehouse
Station, NJ, U.S.A.), which, until that point, had been
considered a very promising chemopreventive agent
for colorectal adenomas. In late December, data from
the Adenoma Prevention with Celecoxib trial 51
showed a similar association between celecoxib and
cardiovascular risk. Consequently, the MAP.3 steeringNCIC CTG MAP.3 TRIAL
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committee decided to halt the trial and revise the
protocol.
The revised MAP.3 study now compares exemes-
tane to placebo in a 1:1 ratio in 4560 postmenopausal
women who are 35 years of age or older and at in-
creased risk for the development of breast cancer. For
the purposes of this protocol, “increased risk” is de-
fined as being over the age of 60, or having a Gail
score greater than 1.65, or having a prior atypical
breast biopsy (atypical ductal hyperplasia, atypical
lobular hyperplasia, or lobular carcinoma in situ), or
having a prior diagnosis of DCIS that was treated with
a mastectomy. Women are stratified on their Gail
score (£2 vs. >2) and current low-dose (<100 mg
daily) aspirin use (yes vs. no) before being randomly
allocated to the treatment or placebo group.
4.2 Rationale for Placebo
Despite the fact that tamoxifen has been approved as
a means to reduce breast cancer risk in women who
would be eligible for this trial, it was decided that the
use of a placebo control arm was justified for several
reasons:
• Although tamoxifen is approved for the indica-
tion of reducing the short-term incidence of breast
cancer, many women whose level of risk would
qualify them for the prescription of tamoxifen
refuse the drug because of its toxicity profile 52–55.
Raloxifene is another option that women may con-
sider for breast cancer risk reduction, although it
is not yet approved for that indication. However,
although the risk profile for raloxifene may be
better than that for tamoxifen, it is still associated
with increased risk of thromboembolic events and
decreased sexual function 27. Therefore, there re-
mains a population of women eligible for this trial
who have chosen or will choose, even after ap-
propriate counselling, to avoid taking tamoxifen
or raloxifene. These women may well wish to enter
a placebo-controlled trial where the agents under
study may have more favourable toxicity profiles.
• The ASCO Technology Assessment of Pharmaco-
logic Interventions for Breast Cancer Risk Re-
duction Including Tamoxifen, Raloxifene and
Aromatase Inhibition 56 concluded that “placebo
controls are appropriate for breast cancer risk re-
duction trials since no intervention has been dem-
onstrated to favorably impact net health or
survival.” Although the MAP.3 trial is not expected
to demonstrate an impact on survival, the results
may well indicate a more favourable therapeutic
ratio for exemestane than for tamoxifen or
raloxifene.
• The placebo arm will allow for a true determina-
tion of efficacy in reducing invasive breast can-
cer, of adverse effects, and of impact on overall
and menopausal-specific quality of life.
4.3 Study Procedures
Women enrolled in the MAP.3 research study will have
a bone-mineral density test and a mammogram be-
fore being randomized. Women can be enrolled at
centres in Canada, the United States, or Spain. Par-
ticipants will be asked to return to their local study
centre twice during the first year, at 6 and 12 months,
and then annually for follow-up visits for the remain-
ing 4 years of the study. At each visit, participants
will be given a new supply of the study medications
and will be asked to answer questions about their
quality of life and about any illnesses or discomfort
they may have experienced since their last visit. At
each annual visit, participants will undergo a physi-
cal and health exam and a mammogram. At three dif-
ferent times during the study, serum samples will also
be taken for hormone testing. If additional consent
has been given for DNA testing, a blood sample taken
at baseline will be stored for future genetic testing.
4.4 Study Goals and Population
The main objective of the MAP.3 trial is to compare
the incidence of breast cancer in the two treatment
groups. Information will also be recorded and com-
pared between treatment groups on clinical bone frac-
tures, cardiovascular events, quality of life, tolerability
and safety, and incidences of other malignancies. A
companion study to evaluate the long-term effects of
exemestane on bone density and bone biomarkers is
planned for a subset of participating sites.
Some of the biggest challenges of conducting a
breast cancer prevention trial include recruiting
women from the general population and defining the
groups at high-risk for the development of breast
cancer that are most eligible for chemoprevention.
Well established cancer cooperative groups with af-
filiated clinical research centers in North America,
Europe, and Australia are available to help with re-
cruitment of cancer patients into therapeutic trials.
However, that model is not so easy to replicate for
cancer prevention trials. The clinicians that typically
see well women are more likely to be primary care
physicians or other internal specialists such as gyne-
cologists. However, primary care physicians in par-
ticular do not appear to be comfortable prescribing
chemoprevention medication 57–59, and based on re-
sults from a recent national survey in the United
States, the decision to prescribe tamoxifen was greatly
affected by logistics and the ability of the physician
to determine eligibility 59.
For the MAP.3 trial to be feasible, the NCIC CTG had
to assemble a consortium of clinical researchers in
Canada and the United States who were committed
to cancer prevention research and who had partici-
pated in earlier prevention trials with the Women’s
Heath Initiative (WHI) or the National Surgical Adju-
vant Breast and Bowel Project. Nonetheless, recruit-RICHARDSON et al.
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ing to chemoprevention trials is still very challeng-
ing, even for experienced research centres. To be suc-
cessful, each site must consider numerous recruitment
strategies. Some of the most successful strategies to
date on MAP.3 include mass mailings, targeting of
high-risk screening clinics, and targeting of “en-
riched” lists (that is, women who participated in the
WHI observational study and expressed an interest in
participating in future cancer prevention research).
Cancer prevention trials tend to be dauntingly
large, particularly if cancer is the primary endpoint.
The large sample size is necessary because cancer is
a very rare occurrence in the general population, and
there is a need to complete the study in a reasonable
period of time (that is, 5 years). Selecting a study
sample that has a higher-than-average risk of devel-
oping cancer is one strategy to increase the event rate
in a fixed period and thereby reduce the required
sample size.
Risk prediction models can be included in the
design of chemoprevention studies to help identify
high-risk populations for an assessment of the effects
of interventions and construction of risk–benefit in-
dices for preventive interventions 60. The Gail model
is one such existing model that has modest predic-
tive ability 61. Based on six well-established risk fac-
tors (age, age at menarche, age at first birth,
first-degree family history of breast cancer, prior
breast biopsy, and race), the Gail model calculates a
woman’s 5-year risk (probability) of developing
breast cancer and compares it with the average risk
for a woman of the same age and race or ethnicity
from the general U.S. population 62.
Age is one of the most important risk factors for
breast cancer. An average 60-year-old woman has a
Gail score of 1.8%; an average 35-year-old woman
has a Gail score of 0.3%. By designing a prevention
trial with a minimum Gail score requirement of 1.66%
for women who are under 60 years of age and have
no history of benign breast disease, the expected an-
nual incidence rate (event rate) in the placebo group
(0.60%) will be more than 6 times the annual inci-
dence rate in the general population (0.10%) 63. Ad-
mittedly, estimates of risk could be greatly improved
with the addition of specific genetic profiles with
validated candidate genes, of lifestyle risk factors,
and of mammographic density 64. However, the ap-
peal of the Gail model is that it is reliable, cost-effi-
cient, and easy to use in large-scale breast cancer
prevention trials, in which thousands of women need
to be screened to determine eligibility.
5. SUMMARY
In the 15 years since the first breast cancer preven-
tion trial was initiated 25, several large phase III trials
have consistently demonstrated that tamoxifen—and
more recently, raloxifene—can effectively reduce the
incidence of invasive breast cancer by 50%. How-
ever, these SERMs can also be associated with several
rare, but serious adverse events, which may explain
their low uptake for chemopreventive purposes.
Currently, a great deal of interest exists in the
third-generation  AIs. These agents have demonstrated
excellent efficacy in adjuvant breast cancer trials and
show particular promise in the breast cancer preven-
tion setting, based on the significantly higher reduc-
tion rates for contralateral breast cancer in the groups
of women on an AI than in those on tamoxifen 34,35.
The AIs are generally well tolerated. Side effects
are similar to those of decreased estrogen—hot
flashes, increased blood pressure, and thinning of
bones, for example. However, the toxicity profile of
exemestane may have advantages over the SERMs and
the other AIs. To date, no evidence has been uncov-
ered that, as compared with placebo or tamoxifen,
exemestane is associated with any significant increase
in cardiovascular disease or adverse effect on lipid
profile 65. In addition, because of the weak andro-
genic and anabolic properties of the principal me-
tabolite of exemestane, 17-hydroexemestane 66,
exemestane may have fewer negative effects on bone
metabolism than do other AIs.
Although it is too early to speculate about the
overall efficacy of AIs in chemoprevention and about
their overall safety profile, MAP.3 participants can be
assured that their safety will be closely monitored
and regularly reviewed by a Data Safety and Moni-
toring Committee. One important question that will
arise from the current series of adjuvant and chemo-
prevention trials of AIs is whether distinct pharmaco-
dynamic effects are associated with the nonsteroidal
AIs (anastrozole and letrozole) and the steroidal
aromatase inactivator (exemestane) that would favour
one type of AI over another in the prevention setting.
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